imiquimod has been researched along with phenanthrenes in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Aranda Lopez, P; Freichel, M; Hartmann, AK; Radsak, MP; Schild, H; Stassen, M; Zajac, M | 1 |
Feng, B; He, S; Li, C; Liu, B; Liu, H; Lu, C; Su, Z; Tang, L; Wang, X; Xu, F; Zhao, J; Zheng, G; Zheng, X; Zhu, W; Zhu, Y | 1 |
2 other study(ies) available for imiquimod and phenanthrenes
Article | Year |
---|---|
9-Phenanthrol enhances the generation of an CD8
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aminoquinolines; Animals; Calcium; Cell Degranulation; Cell Movement; Dendritic Cells; Humans; Imiquimod; Immunity, Innate; Mast Cells; Melanoma; Mice; Mice, Inbred C57BL; Mice, Transgenic; Phenanthrenes; Protein Kinase Inhibitors; Skin; Skin Neoplasms; T-Lymphocytes, Cytotoxic; TRPM Cation Channels; Vaccination; Xenograft Model Antitumor Assays | 2017 |
Cryptotanshinone reduces psoriatic epidermal hyperplasia via inhibiting the activation of STAT3.
Topics: Animals; Cell Line; Cell Proliferation; Disease Models, Animal; Drugs, Chinese Herbal; Epidermis; Humans; Hyperplasia; Imiquimod; Keratinocytes; Male; Mice, Inbred C57BL; Phenanthrenes; Psoriasis; STAT3 Transcription Factor | 2018 |